would be great considering the great news yesterday.

Anyone else on this site invested in Neuropharm?

News imminant on the JV, massive upside potential.

Key points:

- Pharma company, developing drugs for Autism, ADHD and OCD, neurological conditions;

- Current market cap (at 22p mid) is approx 6.7 million and cash in the bank of around 7million;

- Market cap crashed February 2009 when rns released noting failure of key drug trials to achieve primary end point;

- Trial result unexpected, as previous trials all successful, some query over dosage levels in active group or whether problems with placebo group. Company looking for a major pharma to partner ongoing development (i.e. in simple terms - dont consider this programme totally failed);

- Edison report 18th March 2009 values company at 40p per share if NPL 2008 a total failure or up to 1.60 a share if NPL 2008 proves to have just 20% success;

- Has been a seller (or two) in the background keeping the price low but looks like they are now clear;

- Company should announce result of NPL- 2008 research review in due course. If a partner is secured the share price expected to increase substantially. Even if you write off NPL-2008 company (per Edison) still valued at 40p per share right now and other programmes for Fragile X and Pediatric OCD have development value.

Seems like this share was hugely oversold in February. We are due an update in H2 of 2009 regarding NPL-2003 and they are looking at getting the JV signed before the Autumn according to recent RNS.

DYOR and GLA

No interest on yesterdays rise? Things are starting to materialise...